AnaptysBio (ANAB) Competitors $20.10 -0.12 (-0.59%) Closing price 04:00 PM EasternExtended Trading$20.20 +0.10 (+0.50%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. OCUL, AGIO, DNLI, GLPG, IDYA, SRPT, BLTE, HRMY, IRON, and MESOShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Galapagos (GLPG), IDEAYA Biosciences (IDYA), Sarepta Therapeutics (SRPT), Belite Bio (BLTE), Harmony Biosciences (HRMY), Disc Medicine (IRON), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Its Competitors Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics Galapagos IDEAYA Biosciences Sarepta Therapeutics Belite Bio Harmony Biosciences Disc Medicine Mesoblast Ocular Therapeutix (NASDAQ:OCUL) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Do analysts prefer OCUL or ANAB? Ocular Therapeutix currently has a consensus price target of $17.20, indicating a potential upside of 44.90%. AnaptysBio has a consensus price target of $46.13, indicating a potential upside of 129.48%. Given AnaptysBio's higher possible upside, analysts clearly believe AnaptysBio is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has more risk and volatility, OCUL or ANAB? Ocular Therapeutix has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. Which has stronger earnings and valuation, OCUL or ANAB? AnaptysBio has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$56.66M36.45-$193.51M-$1.28-9.27AnaptysBio$123.16M4.57-$145.23M-$4.48-4.49 Is OCUL or ANAB more profitable? AnaptysBio has a net margin of -107.66% compared to Ocular Therapeutix's net margin of -382.51%. Ocular Therapeutix's return on equity of -71.92% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% AnaptysBio -107.66%-366.98%-30.58% Do insiders & institutionals believe in OCUL or ANAB? 59.2% of Ocular Therapeutix shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 33.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor OCUL or ANAB? In the previous week, AnaptysBio had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 3 mentions for AnaptysBio and 2 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.46 beat AnaptysBio's score of 0.90 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAnaptysBio beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$562.74M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-4.4920.9030.1925.84Price / Sales4.57386.36473.64122.75Price / CashN/A43.2325.7828.79Price / Book8.639.649.425.99Net Income-$145.23M-$54.08M$3.27B$265.29M7 Day Performance0.40%2.62%2.05%2.53%1 Month Performance-25.39%4.05%3.58%0.93%1 Year Performance-46.75%9.48%30.09%18.70% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.9779 of 5 stars$20.10-0.6%$46.13+129.5%-46.4%$562.74M$123.16M-4.49100OCULOcular Therapeutix4.0529 of 5 stars$12.31-2.5%$17.20+39.7%+35.0%$2.20B$63.72M-9.62230AGIOAgios Pharmaceuticals4.3571 of 5 stars$37.45+1.2%$56.33+50.4%-16.1%$2.15B$36.50M3.40390Positive NewsDNLIDenali Therapeutics4.1997 of 5 stars$14.82+0.8%$33.62+126.8%-37.5%$2.15B$330.53M-5.29430GLPGGalapagos0.131 of 5 stars$32.91+1.4%$25.33-23.0%+23.6%$2.14B$275.61M0.001,310IDYAIDEAYA Biosciences4.4499 of 5 stars$24.75+1.7%$48.09+94.3%-36.4%$2.13B$7M-6.5380Positive NewsSRPTSarepta Therapeutics4.5467 of 5 stars$20.99-3.8%$43.63+107.8%-85.6%$2.13B$1.90B-24.131,372Trending NewsAnalyst ForecastBLTEBelite Bio2.2245 of 5 stars$64.95-2.5%$96.67+48.8%+31.7%$2.12BN/A-41.9010HRMYHarmony Biosciences4.6544 of 5 stars$36.41-1.2%$51.00+40.1%+4.1%$2.12B$714.73M11.75200Positive NewsIRONDisc Medicine3.5445 of 5 stars$58.84-1.7%$96.18+63.5%+22.1%$2.08BN/A-13.1630Positive NewsMESOMesoblast2.0056 of 5 stars$15.93-2.0%$18.00+13.0%+141.0%$2.08B$5.90M0.0080Upcoming Earnings Related Companies and Tools Related Companies Ocular Therapeutix Competitors Agios Pharmaceuticals Competitors Denali Therapeutics Competitors Galapagos Competitors IDEAYA Biosciences Competitors Sarepta Therapeutics Competitors Belite Bio Competitors Harmony Biosciences Competitors Disc Medicine Competitors Mesoblast Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access